Abcuro Inc, a developer of therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, has secured $42 million in Series A-1 financing. Mass General Brigham Ventures and Sanofi Ventures led the round.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: